# A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer

> **NCT06692959** · PHASE2 · RECRUITING · sponsor: **University of Southampton** · enrollment: 44 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** PD-1 vaccine IMU-201 (PD1-Vaxx)

## Key facts

- **NCT ID:** NCT06692959
- **Lead sponsor:** University of Southampton
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-16
- **Primary completion:** 2027-03-31
- **Final completion:** 2029-01-31
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2026-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06692959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06692959, "A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06692959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*